BaseSpace
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Leukocyte, Anticancer prodrugs, Rosiglitazone, rs2230926, BRCA1, Ischemia)
Bookmark Forward

QuickView for CCL2 (gene)


Body Atlas

Most Correlated Tissues

  1. Smooth muscle
  2. Vena cava
  3. Lung
  4. Omental adipose tissue
  5. Aorta
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Disease due to Orthopoxvirus
  2. Neural tube defect
  3. Arrhythmogenic right ventricular dysplasia
  4. Severe acute respiratory syndrome
  5. Viral disease
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. Taxol
  2. Tgfb1 protein, rat
  3. SB-590885
  4. cumene
  5. HI 6
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. MIR4709
  2. FGFR1
  3. TSR2
  4. TSC2
  5. FGFR1
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

Loading...
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Expression of CCL2 signaling pathway genes in patients with periodontitis and atherosclerosis.
  2. Ultrasensitive CCL2 Detection in Urine for Diabetic Nephropathy Diagnosis Using a WS2-Based Plasmoni…
  3. Deficiency in astrocyte CCL2 production reduces neuroimmune control of Toxoplasma gondii infection.
  4. CCL2 is a key regulator and therapeutic target for periodontitis.
  5. Therapeutic delivery of CCL2 modulates immune response and restores host-microbe homeostasis.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy
  2. Role of CCL2 in Alcoholic Liver Diseases
  3. A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in P…
  4. Drug Resistant Epilepsy: Clinical and Genetic Study
  5. Contribution of Inflammation and Neuronal Integrity Markers in Patients With First-episode Conversiv…
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.